QualityDipStocks / Health Care · Pharmaceuticals
Grifols GRFS
Outside our quality screen, so we don’t track its dips. It’s 12% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its filings are too old.
- Fair value est.
- n/a
- Market Value
- —
- Off 52-wk high
- −12%
- Risk vs market
- Market-likebeta 0.90
1 bullish · 2 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for GRFS: Latest cash-flow data in SEC XBRL ends 2024-12-31, too old to use. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much GRFS moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 2.5× the S&P 500’s.
- Beta vs S&P 500
- 0.90
- Volatility
- 33% vs 13% SPY
- Correlation SPY
- 0.35
- Correlation QQQ
- 0.24
Valuation details
FCF value $20.55
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 1 of 5
ValuationFree-cash-flow yield of 9.7%: $0.6B of free cash in the last 12 months on a $6B market cap.
Top bearish points 2 of 5
Balance sheetNet debt is 5.4× a year of EBITDA, a heavy load.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%; sales down vs the year-ago quarter; net debt 5.4× EBITDA (limit 3×).
All fundamentals
from SEC filings
No fundamentals for Grifols: Latest SEC XBRL statements end 2024-12-31, too old to use. We show nothing rather than guess.
The business
FCF $0.6B · Sales −1%
- Free cash flow, 12 months$0.6B
- Free-cash-flow yield9.7%
- Free-cash-flow margin8%
- Gross margin38%
- Operating margin16%
- Return on invested capital9%
- Return on equity7%
- Sales growth (latest quarter vs year-ago quarter)−1%
- Net debt / EBITDA5.4×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $8.51
- 52-wk lowlowest close, 1 year$7.02−17.5%
- PriceMon Nov 2 close$8.51you are here
- 52-wk highhighest close, 1 year$9.72+14.2%
Momentum & 52-week range
RSI 75 · 5 days +7.4%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
GRFS is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Grifols in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.